For human xenograft experiments in mice and administration of primary human material not suspected of harboring a human pathogen, standard ARP handling practices for housing and cage changing can be ...
Silexion Therapeutics Corp. (NASDAQ:SLXN) released new preclinical data for SIL-204, its next-generation siRNA therapeutic ...
This was further validated in an HCC xenograft mouse model, where the combination of shCD39-CAR-T cells with mdivi-1 resulted ...
New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...
Relevant preclinical models are vital to ensuring that time and money are invested in advancing the most effective drug candidates. While traditional cell line-derived xenograft (CDX) models generated ...
The primary focus Patient-Derived Xenograft (PDX) Core is to develop, and provide to the Baylor PDX community, computational and bioinformatics infrastructure to support large scale generation, ...
Dewpoint Therapeutics’ second development candidate, DPTX3496 is an oral, small molecule acting via a novel ...
Silexion Therapeutics (SLXN) announced new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. The findings ...